- Case Report
- Open Access
Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report
© Brogan et al; licensee BioMed Central Ltd. 2009
- Received: 19 August 2008
- Accepted: 21 January 2009
- Published: 21 January 2009
This case report describes an 8 year old boy with IVIG resistant Kawasaki disease complicated by severe bilateral coronary artery aneurysms successfully treated with infliximab, a monoclonal antibody against tumour necrosis factor alpha.
- Kawasaki Disease
- Right Coronary Artery
- Left Coronary Artery
- Left Main Coronary Artery
Kawasaki disease (KD) is associated with the development of systemic vasculitis complicated by coronary and peripheral arterial aneurysms, and myocardial infarction in some patients . KD has an incidence of 8/100 000 children in the UK, and has superseded rheumatic fever in that KD is now the commonest cause of acquired heart disease in children in the United Kingdom and the USA . Treatment with intravenous immunoglobulin (IVIG) and aspirin reduces the incidence of coronary artery lesions (CAL) from approximately 20–40% to <5% [1, 2], although recently in the UK we and others have reported an alarmingly higher incidence of CAL despite IVIG therapy, probably relating to delayed diagnosis of KD in the UK [3, 4]. It is generally accepted that an as yet undefined infectious trigger in a genetically predisposed individual results in the disease .
Despite intensive research into the illness the cause remains unknown, and although there have been significant improvements in diagnosis and treatment of children with the disease there are still a number of important unanswered questions regarding aetiopathogenesis , treatment of IVIG resistant cases, and long-term outlook . This case report describes an 8 year old male with severe coronary artery aneurysms (CAA) and ongoing inflammation despite therapy with IVIG, aspirin and corticosteroids, treated successfully with infliximab.
The patient was an eight year old boy presenting to his local hospital with a three day history of pyrexia, irritability, erythematous rash in the groin, bilateral knee arthritis and generalised arthralgia, and a one day history of bilateral non-purulent conjunctivitis. There was no prior past medical or family history of note and he was fully immunised. Examination revealed red, cracked lips but there was no lymphadenopathy or clinically overt focus of infection. Laboratory investigations at that stage revealed haemoglobin (Hb) 12.6 g/dL (normal reference range 11.5–15.5 g/dL), white cell count (WCC) 10.6 × 109/L (4.5–13.5 × 109/L), platelets 444 × 109/L (150–450 × 109/L), erythrocyte sedimentation rate (ESR) 80 mm/hr (0–10 mm/hr), C-reactive protein (CRP) 143 mg/L (<20 mg/L) and Albumin (Alb) 32 g/L. He was initially treated symptomatically with paracetamol, ibuprofen and broad spectrum antimicrobials, but with no response. All blood cultures and serology for infections were subsequently negative. By day 7 of illness he had persistent spiking fever up to 40.2°C, and developed desquamation of his palms and soles, and severe colicky central abdominal pain without peritonitis. He had also developed worsening arthritis in his ankles, wrists and elbows. Repeat laboratory tests revealed ongoing severe systemic acute phase responses with ESR 99 mm/hr, CRP 185 mg/L, platelets to 512 × 109/L and total WCC 11.5 × 109/L. Ultrasound of abdomen and hips and bone scan revealed no abnormalities.
Rheumatoid factor, anti-nuclear antibody, autoantibodies to extractable nuclear antigens, and anti-neutrophil cytoplasmic antibodies all proved negative. Renal and liver function tests were normal and a bone marrow aspirate demonstrated reactive inflammatory changes with no evidence of malignancy. Electrocardiogram (ECG) revealed an episode of Wenckebach heart block with baseline tachycardia (heart rate 100 beats per minute). Thereafter, echocardiography revealed both right and left coronary artery dilation of 5 mm and a diagnosis of complete Kawasaki disease was confirmed.
On day 14 of illness, the patient was given Intravenous Immunoglobulin (IVIG) 2 g/kg over 12 hours and high dose aspirin. Within 48 hours there was persisting fever and ongoing severe acute phase response (CRP at 206 mg/L, WCC 15.4 × 109/L and platelets 822 × 109/L).
A second dose of IVIG 2 g/kg was administered 17 days after disease onset. Despite this the patient remained febrile with persisting arthritis and irritability. A repeat echocardiogram on day 18 of illness revealed left coronary artery (LCA) dilation of 5.3 mm and right coronary artery (RCA) of 4.3 mm. His Hb dropped to 6.4 g/dL requiring transfusion. The patient had also developed a systolic murmur and repeat echocardiography showed further RCA dilation of 7 mm and LCA dilation of 5 mm.
Thereafter the CAL progressively improved and follow-up echocardiography 5 months after onset of KD revealed partial resolution of his coronary dilation: RCA 3.4 mm and LCA 4 mm proximally and 5.7 mm distally. Formal coronary digital subtraction arteriography 9 months after disease onset demonstrated minor ectasia of the left main coronary artery (LCA) and proximal circumflex and proximal left anterior descending artery. This was most noticeable on the LAD just at the origin of the diagonal artery. The right coronary artery was of a normal caliber (Figure 1C).
Treatment of KD is aimed at reducing inflammation, preventing the formation of CAA and arterial thrombosis . Up to 15% of patients do not respond to a single dose of IVIG and a second dose may be required [2, 8], although such IVIG resistant cases may be at higher risk of CAL . Recently it has been suggested that corticosteroids may be used with comparable efficacy to a second dose of IVIG for children who fail to respond to the first dose .
Our patient was given his first dose of IVIG on illness day 14, but failed to defervesce after two doses of IVIG. In IVIG resistant KD a number of therapies are reported to be of benefit such as corticosteroid therapy , plasma exchange, ulinastatin, and therapy directed at blockade of tumour necrosis factor alpha (TNF-α) . Of these, most attention has focused on corticosteroids either for IVIG resistance  or as adjunctive first line treatment in combination with IVIG [11, 12]. However, evidence based guidance for alternative treatment if steroids fail (as in our patient) are lacking. Our patient was treated with a single dose of infliximab 6 mg/kg. After the infusion his fever and other systemic symptoms promptly resolved. Encouragingly his severe CAAs began to resolve although we cannot attribute this to infliximab alone. Nonetheless our case highlights the potential for anti-TNF-α therapy in the acute management of CAA in the face of ongoing recalcitrant systemic inflammation.
Previously published reports of Infliximab for the treatment of IVIG resistant Kawasaki disease.
Number of cases
Weiss et al
IVIG × 8
MP × 8
5 mg/kg × 3
Resolution of fever post Infliximab; no further progression of CAA
Oishi et al
CAA of RCA and LCA
IVIG × 3 (first two doses at 1 g/kg, 3rd dose at 2 g/Kg)
MP × 2
5 mg/kg × 1
Defervesced within 24 hours of infliximab; developed transient urticaria post infliximab
Girish et al
CAA of RCA and LCA
IVIG × 2
MP × 3
5 mg/kg × 1
Immediate defervescence post infliximab
Burns et al
2.6 years (0.12–13.1);
All received at least 2 doses of IVIG;
8/17 MP (1–3 doses)
5 mg/kg × 1 (15/17 patients); 10 mg/kg × 1 (2/17 patients)
13/16 febrile patients defervesced post infliximab; 1 patient died of cardiac arrest related to CAA 53 days after infliximab
Stenbog et al
11 weeks (M)
33 weeks (M)
Both received at least 2 doses of IVIG;
6 mg/kg × 3
Prompt defervescence and regression of CAA in both cases
O'Connor et al
Giant CAA and peripheral gangrene
IVIG × 2
MP × 3
5 mg/kg × 2
Fever resolved after second dose of infliximab; patient received pred PO (for 2 weeks) after infliximab
Burns et al
1.7 years (0.7–3.1)
sex not documented in 4 patients receiving infliximab after 2 doses of IVIG
Single dose of IVIG (n = 12);
IVIG × 2 (n = 4)
5 mg/kg × 1
11/12 patients receiving infliximab after a single IVIG dose defervesced within 24 hours; 2/4 patients receiving infliximab after 2 doses of IVIG defervesced; no serious adverse events
Since the recognition that IVIG could reduce the morbidity and mortality of KD, treatment of this condition has been protocol driven. Although authorities differ in their advocacy for a variety of treatment protocols, it is likely that the success of therapeutic intervention in KD is due to modulation of the causes and/or propagators of inflammation. As such it is perhaps important to re-evaluate the current prescriptive approach to the management of KD. Is it correct to persist with interventions in a patient in whom there is little evidence of clinical and/or laboratory remission? If ongoing inflammation were damaging to the vasculature, it would seem logical to assess the success (or lack of) of any interventions on the basis of cessation of clinical/laboratory inflammation.
If rapid and effective interruption of inflammation is a primary target of KD therapy, TNF-α blockade may be useful as first line therapy, either in place of or adjunctive to IVIG for the initial treatment of KD. In that context in the UK the cost of a single dose of 2 g/kg IVIG exceeds that of a single dose of infliximab, and therefore infliximab could provide a cheaper alternative to IVIG in the future. As yet, however, we are unaware of any case reports describing the use of infliximab or other anti-TNF-α therapy as first line therapy for KD, and this currently remains an experimental albeit promising novel therapy for IVIG resistant KD.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Brogan PA, Bose A, Burgner D, Shingadia D, Tulloh R, Michie C, Klein N, Booy R, Levin M, Dillon MJ: Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child. 2002, 86: 286-90. 10.1136/adc.86.4.286.PubMed CentralView ArticlePubMedGoogle Scholar
- Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association: Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004, 114: 1708-33. 10.1542/peds.2004-2182.View ArticlePubMedGoogle Scholar
- Gandhi A, Wilson DG: Incomplete Kawasaki disease: not to be forgotten. Arch Dis Child. 2006, 91: 276-7. 10.1136/adc.2005.086884.PubMed CentralView ArticlePubMedGoogle Scholar
- Brogan PA, Shah V, Clarke LA, Dillon MJ, Klein N: T cell activation profiles in Kawasaki syndrome. Clin Exp Immunol. 2008, 151: 267-74.PubMed CentralView ArticlePubMedGoogle Scholar
- Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, Nakamura Y, Yanagawa H, Wakui K, Fukushima Y, Kishi F, Hamamoto K, Terai M, Sato Y, Ouchi K, Saji T, Nariai A, Kaburagi Y, Yoshikawa T, Suzuki K, Tanaka T, Nagai T, Cho H, Fujino A, Sekine A, Nakamichi R, Tsunoda T, Kawasaki T, Nakamura Y, Hata A: ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008, 40: 35-42. 10.1038/ng.2007.59.PubMed CentralView ArticlePubMedGoogle Scholar
- Brogan PA: What's new in the aetiopathogenesis of vasculitis?. Pediatr Nephrol. 2007, 22: 1083-94. 10.1007/s00467-007-0450-1.View ArticlePubMedGoogle Scholar
- Durongpisitkul K, Gururaj VJ, Park JM, Martin CF: The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995, 96: 1057-61.PubMedGoogle Scholar
- Fong NC, Hui YW, Li CK, Chiu MC: Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness. Pediatr Cardiol. 2004, 25: 31-4. 10.1007/s00246-003-0558-4.View ArticlePubMedGoogle Scholar
- Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y: Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008, 93: 142-6. 10.1136/adc.2007.126144.View ArticlePubMedGoogle Scholar
- Dale RC, Saleem MA, Daw S, Dillon MJ: Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr. 2000, 137: 723-6. 10.1067/mpd.2000.108444.View ArticlePubMedGoogle Scholar
- Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A: A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006, 149: 336-41. 10.1016/j.jpeds.2006.05.025.View ArticlePubMedGoogle Scholar
- Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP, Pediatric Heart Network Investigators: Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007, 356: 663-75. 10.1056/NEJMoa061235.View ArticlePubMedGoogle Scholar
- Lau AC, Duong TT, Ito S, Yeung RS: Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis Rheum. 2008, 58: 854-63. 10.1002/art.23225.View ArticlePubMedGoogle Scholar
- Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS: Infliximab as a novel therapy for refractory Kawasaki disease. J of Rheumatol. 2004, 31: 808-810.Google Scholar
- Oishi T, Fujieda M, Shiraishi T, Ono M, Inoue K, Takahashi A, Ogura H, Wakiguchi H: Infliximab treatment for refractory kawasaki disease with coronary artery aneurysm. Circ J. 2008, 72: 850-2. 10.1253/circj.72.850.View ArticlePubMedGoogle Scholar
- Girish M, Subramaniam G: Infliximab treatment in refractory Kawasaki syndrome. Indian J Pediatr. 2008, 75: 521-2. 10.1007/s12098-008-0084-8.View ArticlePubMedGoogle Scholar
- Stenbog EV, Windelborg B, Horlyck A, Herlin T: The effect of TNFalpha blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol. 2006, 35: 318-21. 10.1080/03009740600588228.View ArticlePubMedGoogle Scholar
- Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, Balfour I, Shen CA, Michel ED, Shulman ST, Melish ME: Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005, 146: 662-7. 10.1016/j.jpeds.2004.12.022.View ArticlePubMedGoogle Scholar
- Stenbog EV, Windelborg B, Horlyck A, Herlin T: The effect of TNF blockade in complicated, refractory Kawasaki disease. Scandinavian Journal of Rheumatology. 2006, 35: 318-321. 10.1080/03009740600588228.View ArticlePubMedGoogle Scholar
- O'Connor MJ, Saulsbury FT: Incomplete and atypical Kawasaki disease in a young infant: Severe, recalcitrant disease responsive to infliximab. Clin Pediatr. 2007, 46: 345-348. 10.1177/0009922806294842.View ArticleGoogle Scholar
- Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O: Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008, 153: 833-838. 10.1016/j.jpeds.2008.06.011.PubMed CentralView ArticlePubMedGoogle Scholar
- Clinical Guidelines for immunoglobulin use from Department of Health. [http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085235]
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.